Content about Lupron Depot

October 28, 2011
FDA approves supplemental new drug application for Abbott's Lupron Depot-PED

The Food and Drug Administration has approved a supplemental new drug application related to a drug made by Abbott, the company said.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a supplemental new drug application related to a drug made by Abbott, the company said.

June 20, 2011
Abbott receives FDA approval for Lupron Depot

The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.